Johnson and Johnson stated that it made a $1 billion deal with the US government to create enough coronavirus vaccines to supply more than 1 billion doses.
This new vaccine is one that they are currently testing and they believe that they will be able to start experimental testing on humans by September. Their goal is to have the vaccine ready for “emergency use” in early 2021.
Typically, it takes about 18 months for vaccines to be tested, approved, and then also manufactured. But under the emergency use authorization that they may get, the batches will be ready in about one year or even under that time.
I firmly believe that we will have a vaccine getting manufactured and distributed in early 2021 whether it is this vaccine or one created by another company.
The question is what does this mean for travel?
By the time that vaccines are readily available, I expect there to be a huge surge in travel. I think people will still be a bit cautious (and will take sanitation seriously) which is obviously a good thing but they will still want to get out and travel freely about the country and the world.
But I am very curious to see what happens in the travel space after the initial wave of cases dies down in a couple of months and then there is this weird period of about 6 to 8 months where we are just waiting on the vaccine.
There will be more treatments available for coronavirus in that time which will help reduce mortality rates and severe cases but I wonder if the public will feel safe until they have access to a proven vaccine?
So I am curious about you readers and how you feel about traveling. Let me know below if you think you will fell comfortable traveling before a vaccine is available to you.
Create your own user feedback survey
Daniel Gillaspia is the Founder of UponArriving.com and the credit card app, WalletFlo. He is a former attorney turned travel expert covering destinations along with TSA, airline, and hotel policies. Since 2014, his content has been featured in publications such as National Geographic, Smithsonian Magazine, and CNBC. Read my bio.